Technical Analysis for ALLR - Allarity Therapeutics, Inc.
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Weak or Absent | Down | Down | Down |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Narrow Range Bar | Range Contraction | 0.00% | |
Wide Bands | Range Expansion | 0.00% | |
Up 3 Days in a Row | Strength | 0.00% | |
Oversold Stochastic | Weakness | 0.00% | |
Stochastic Buy Signal | Bullish | 6.43% | |
NR7 | Range Contraction | 6.43% | |
Narrow Range Bar | Range Contraction | 6.43% | |
Lower Bollinger Band Walk | Weakness | 6.43% | |
Inside Day | Range Contraction | 6.43% | |
Wide Bands | Range Expansion | 6.43% |
Alert | Time |
---|---|
Up 5% | about 6 hours ago |
Rose Above Previous Day's High | about 6 hours ago |
Up 3% | about 6 hours ago |
60 Minute Opening Range Breakout | about 7 hours ago |
60 Minute Opening Range Breakdown | about 9 hours ago |
Get a Trading Assistant
- Earnings date: 05/15/2023
Allarity Therapeutics, Inc. Description
Allarity Therapeutics A/S develops various therapeutic candidates for the treatment of cancer using drug-specific companion diagnostics (cDx) generated by its drug response predictor technology. Its lead therapeutic candidate is dovitinib, a second-generation pan-tyrosine kinase inhibitor with the ability to inhibit numerous classes of tumor-driving tyrosine kinases, including FGFR, VEGFR, PDGFR, c-Kit, Flt-3, and CSF-1. The company's therapeutic candidates also include stenoparib, selective inhibitor of the key DNA damage repair enzyme poly-ADP-ribose polymerase; and IXEMPRA, a selective microtubule inhibitor that interferes with cancer cell division through mitotic arrest. It also developing other therapeutic candidates comprising LiPlaCis, a targeted liposomal formulation of Cisplatin; 2X-111, a targeted liposomal formulation of Doxorubicin; and Irofulven, a DNA damaging agent. The company was founded in 2004 and is headquartered in Horsholm, Denmark.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Cancer Health Sciences Drugs Treatment Of Cancer Enzymes Protein Kinase Inhibitor Tyrosine Kinase Liposome Doxorubicin
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 269.8 |
52 Week Low | 0.185 |
Average Volume | 6,258,580 |
200-Day Moving Average | 7.58 |
50-Day Moving Average | 0.72 |
20-Day Moving Average | 0.42 |
10-Day Moving Average | 0.32 |
Average True Range | 0.09 |
RSI (14) | 18.03 |
ADX | 18.83 |
+DI | 18.53 |
-DI | 34.11 |
Chandelier Exit (Long, 3 ATRs) | 0.41 |
Chandelier Exit (Short, 3 ATRs) | 0.46 |
Upper Bollinger Bands | 0.70 |
Lower Bollinger Band | 0.15 |
Percent B (%b) | 0.14 |
BandWidth | 129.73 |
MACD Line | -0.20 |
MACD Signal Line | -0.22 |
MACD Histogram | 0.0213 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 0.27 | ||||
Resistance 3 (R3) | 0.27 | 0.25 | 0.26 | ||
Resistance 2 (R2) | 0.25 | 0.24 | 0.25 | 0.26 | |
Resistance 1 (R1) | 0.24 | 0.23 | 0.24 | 0.24 | 0.26 |
Pivot Point | 0.22 | 0.22 | 0.22 | 0.22 | 0.22 |
Support 1 (S1) | 0.21 | 0.21 | 0.22 | 0.21 | 0.20 |
Support 2 (S2) | 0.19 | 0.21 | 0.20 | 0.19 | |
Support 3 (S3) | 0.18 | 0.19 | 0.19 | ||
Support 4 (S4) | 0.19 |